CERN Members are a collaborative network of researchers and medical providers who are constantly making new discoveries.
We are committed to being a resource to the ependymoma community regarding the latest in ependymoma research, diagnosis, treatment, and the impact on patients and their caregivers.
Discoveries from the 2020 CERN Robert Connor Dawes Pediatric Fellowship, supported by the National Brain Tumor Society, to Dr. Chan Chung in Dr. Sriram Venneti’s laboratory at the University of Michigan, were instrumental in helping to win an esteemed $3 million R01 grant from the National Cancer Institute (NCI).
NCI-CONNECT leads Survivorship Care in Neuro-Oncology Workshop in partnership with advocacy organizations including the CERN Foundation and National Brain Tumor Society
The CERN Foundation a program of the National Brain Tumor Society, proudly endorses the Proceedings of the Survivorship Care in Neuro-Oncology Workshop Sponsored by the Comprehensive Oncology Networking Evaluating Rare CNS Tumors (NCI-CONNECT), which summarizes a two-day virtual workshop held virtually on June 20 and 21, 2021, addressing the advancement of survivorship care for people living with primary central nervous system cancers.
In cell and mouse models, metformin suppressed tumor growth in group A posterior fossa ependymomas.
— Categories: Ependymoma Research Articles Posted on July 24, 2020
Ependymomas are glial tumors that occur throughout the central nervous system. Of the nine distinct molecular types of ependymoma, posterior fossa A (PFA) ependymomas, found in the hindbrain of infants and young children, are the most prevalent type. In this publication, the investigators have identified a metabolic-epigenomic link in PFA ependymomas that informs the phenotype of PFA ependymoma and possible development of novel therapeutic strategies for these lethal cancers.
— Categories: Ependymoma Research Articles Posted on March 7, 2020
The European Association of Neuro-Oncology (EANO) have published guidelines for the diagnosis and treatment of ependymoma tumors.
— Categories: Ependymoma Research Articles Posted on September 5, 2018
View a case-based review of a 46-year-old woman with a spinal cord ependymoma. Top neuro-oncologists discuss the current classification and treatment for ependymoma.
— Categories: Ependymoma Research Articles Posted on August 9, 2018
Santhosh Upadhyaya, MD, Neuro-oncologist at St. Jude Children’s Research Hospital discusses radiation therapy for young children under the age of 3 who have ependymoma.
— Categories: Ependymoma Research Articles Posted on January 9, 2018
Scientists have now developed a molecular approach that may open new treatment prospects for ependymoma.
— Categories: Ependymoma Research Articles Posted on December 5, 2017
Ependymomas are rare neuroepithelial primary central nervous system (CNS) tumors that affect children and adult patients in which they make up 1.8% of all primary CNS tumors. In this article, authors review the classification, pathology and current clinical approaches.
— Categories: Ependymoma Research Articles Posted on January 18, 2017
Ependymomas are brain or spinal tumors that can occur in people of all ages within the central nervous system. The prognosis of these tumors does not necessarily correlate with tumor grade and there are no genetic mutations that can be used to classify these tumors.
Deriving Therapies for Children with Primary CNS Tumors Using Pharmacokinetic Modeling and Simulation of Cerebral Microdialysis Data
— Categories: Ependymoma Research Articles Posted on June 16, 2014
The treatment of children with ependymoma and CNS tumors continues to be a challenge despite recent advances in technology and diagnostics. In this overview, St. Jude Children’s Research Hospital describes their approach for identifying and evaluating active anticancer drugs through a process that enables rational translation from the lab to the clinic.
— Categories: Ependymoma Research Articles Posted on September 13, 2013
The diagnosis of a brain tumors, including ependymoma, in children can impact not only the child but the entire family. This study is a qualitative study.
A Molecular Biology and Phase II Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study
— Categories: Ependymoma Research Articles Posted on September 11, 2013
The pediatric brain tumor consortium conducted a molecular biology (MB) and phase II study to estimate inhibition of tumor ERBB signaling and sustained responses by lapatinib in children with recurrent CNS malignancies.
Study Supports the Use of Adjuvant Radiation Therapy in Management of Pediatric Myxopapillary Ependymoma
— Categories: Ependymoma Research Articles Posted on February 18, 2013
Historically, myxopapillary ependymoma has been considered a benign neoplasm, often cured with surgical resection. However, this manuscript questions this dogma.
— Categories: Ependymoma Research Articles Posted on February 15, 2013
This article represents a secondary analysis of existing published data of the impact of the extent of surgery and adjuvant radiation therapy in adults with spinal cord ependymoma.
Increased Expression of Tumor-associated Antigens in Pediatric and Adult Ependymomas: Implication for Vaccine Therapy
— Categories: Ependymoma Research Articles Posted on January 9, 2013
A group of investigators at the University of Pittsburgh are investigating a peptide-based vaccine therapy targeting EphA2, IL-13Ra2, and Survinin for the treatment of pediatric tumors. This study explored whether these targets are overexrpressed in ependymoma as they are in other gliomas.
Pediatric Study Group Publish Paper on Lack of Efficacy of Bevacizumab Plus Irinotecan in Pediatric Recurrent Ependymoma
— Categories: Ependymoma Research Articles Posted on November 14, 2012
This study, conducted by the Pediatric Brain Tumor Consortium, was one component of a wider effort to study the efficacy of bevacizumab in combination with a conventional chemotherapeutic agent (here irinotecan) to treat children with recurrent brain tumors.
Retrospective Evaluation of Factors Associated with Prognosis in Children Treated for Ependymoma in Australia
— Categories: Ependymoma Research Articles Posted on September 5, 2012
A retrospective evaluation of tumor and treatment characteristics of 43 children treated for ependymoma/anaplastic ependymoma treated at New South Wales Cancer Center between 1969 and 2009.
— Categories: Ependymoma Research Articles Posted on August 21, 2012
Achieving a complete removal of the tumor before using radiation is a key factor in controlling the disease in patients with ependymoma. However, due to the tumor’s nature and location, it is difficult to achieve a complete removal of the tumor during the initial surgery without damaging the cranial nerves and surrounding brain tissue.
— Categories: Ependymoma Research Articles Posted on August 10, 2011
Two recent publications address the complications of therapy for people with ependymoma. Researchers explored the impact of location of tumor and radiation on cognitive and psychological outcomes in 23 children with ependymoma.
— Categories: Ependymoma Research Articles Posted on October 25, 2008
The enzymatic subunit of telomerase (hTERT) is an important prognostic marker for paediatric ependymoma. Because of the lack of good, representative pre-clinical models for ependymoma, researchers took advantage of their large cohort of ependymoma patients, some with multiple recurrences, to investigate telomere biology in these tumours.
— Categories: Ependymoma Research Articles Posted on August 22, 2007
Although ependymomas account for only 10% of all childhood brain tumours, this tumour type is particularly common in young children. Because of the potentially severe long-term effects of radiation on the developing central nervous system, over the past 20 years, several studies have focused on the feasibility of using postoperative chemotherapy to delay or even avoiding radiotherapy.
— Categories: Ependymoma Research Articles Posted on July 15, 2007
Because few large studies of pediatric ependymoma treatment are available, the authors believed that a retrospective review of treatment outcomes from a single institution would yield potentially valuable information regarding potential prognostic factors.
— Categories: Ependymoma Research Articles Posted on May 5, 2007
The authors report a retrospective study of 152 adult patients harbouring intracranial ependymomas from 24 French Neurosurgical Centres between 1990 and 2004. All clinico-radiological and follow-up data were analysed and a central pathologic review was performed by two confirmed neuropathologists.
— Categories: Ependymoma Research Articles Posted on December 13, 2006
Pediatric intracranial ependymomas are a heterogeneous group of neoplasms with unpredictable clinical and biologic behavior. As part of ongoing studies to identify potential biologic and therapeutic markers, doctors analyzed the role of human telomere reverse transcriptase (hTERT; the catalytic subunit of telomerase) expression as a prognostic marker for this disease.